Insightec device aids Alzheimer's drug delivery - study

Alzheimer's Disease  credit: Shutterstock
Alzheimer's Disease credit: Shutterstock

A study at the WVU Rockefeller Neuroscience Institute found that Insightec's focused ultrasound device enabled a drug to cross the blood-brain barrier rapidly.

"The New England Journal of Medicine" published an article this month containing interesting results from the use of a device produced by Israeli company Insightec in tandem with a drug for treating Alzheimer’s Disease. This is an initial study that is not part of a protocol for submitting the product for regulatory approval, but it indicates a possible future use of the company’s technology in the huge Alzheimer market, which is crying out for solutions.

The current study, conducted with the WVU Rockefeller Neuroscience Institute, demonstrated that Insightec’s device facilitated the opening of the blood-brain barrier by means of focused ultra-sound energy on a certain region of the brain. This enables the Alzheimer’s treatment drug to be delivered and rapidly reduce the amount of cerebral beta-amyloid plaque characteristic of Alzheimer’s Disease. The researchers used ultra-sound only on half the brain, with the other half serving as a control. In the side of the brain that was treated, the level of plaque was lower, and the response was quicker.

The idea of using this technology has been around for years. Several developments in the past couple of years came together to make the current trial possible and make it very interesting. The blood-brain barrier is a colorful way of describing the fact that blood vessels in the brain convey certain substances to the brain tissue but not others. Some drugs designed for treating the brain do not reach it in large quantities. This is a problem in treating a range of diseases, including brain cancer, for example, which, because of this limitation, is difficult to treat with chemotherapy.

After years without significant innovation in Alzheimer’s treatment, two new drugs have reached the market in the past year, one from Biogen and Eisai, and the other from Eli Lilly. Both are based on antibodies meant to remove amyloid plaque from patients’ brains. In trials of both drugs, a small but apparently real improvement was found in the condition of patients if their levels of plaque fell sufficiently.

This means that not only are there now new drugs for treating Alzheimer’s Disease on the market, but there is also confirmation of an approach that until recently was highly controversial, namely that reducing plaque ameliorates the patient’s condition. There is therefore importance in the finding that opening the blood-brain barrier enabled the drug used to reduce plaque levels more quickly.

The drug used in the trial with Insightec’s technology was Aduhelm, a previous drug from Biogen and Eisai, which just this week was removed from sale. Biogen is focusing on its new drug, but the use of Aduhelm demonstrates how Insightec’s device can improve the effectiveness of an existing drug that was considered only slightly helpful.

Even with drugs considered effective in the first place, the technology could improve their performance and accelerate their action, which is important in the case of Alzheimer’s, a disease that advances rapidly.

"Focused ultrasound provides a new opportunity for Insightec collaborations with drug companies to improve drug delivery to the brain," said Insightec CEO and chairperson Maurice Ferré. "Only 1-2% of drugs can cross the blood-brain barrier, making progress difficult and patient safety challenging when using large systemic drug concentrations. The ability to disrupt the blood-brain barrier to effectively deliver treatment demonstrates the power and potential of using focused ultrasound technology when addressing complex neurological conditions."

The publication of this trial comes at a good period for Insightec, whose financial results are revealed through Elbit Imaging (TASE: EMITF), which is traded on the Tel Aviv Stock Exchange, and directly and indirectly holds 2.5% of Insightec. The largest shareholder in the company is Koch Disruptive Technologies, a subsidiary of Koch Industries.

To date, Insightec has raised some $550 million. The company has brought several focused ultrasound products to market, designed to burn tissues deep inside the body and brain selectively, to treat diseases such as cancer and Parkinson’s. In 2022, the company had revenue of $96 million, but, despite good revenue growth over the years, the cost of the product and of development have it made it difficult for the company to become profitable. Its most recent financials carry a going concern qualification.

The new study points to an application for Insightec’s product that is too far from the market to affect its results substantially in the near future, but the enthusiasm over this new direction could enable it to raise further capital.

Published by Globes, Israel business news - en.globes.co.il - on February 5, 2024.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2024.

Alzheimer's Disease  credit: Shutterstock
Alzheimer's Disease credit: Shutterstock
Tech jobseeker numbers rising  credit: Shutterstock Tech layoffs affecting industry's core

The rise in the number of jobseekers in the technology sector is largest among experienced, mid-level workers in what were once secure roles.

Elon Musk credit: Shutterstock Elon Musk's SpaceX set to launch Israel's Dror satellite

The Dror satellite will serve Israel's communications needs for the next 15 years.

Maurice Ferre illustration Gil Gibli Insightec wins new FDA approval for Parkinson's treatment

The company's revenue is growing, but it is yet to post a profit. CEO Maurice Ferré: The market no longer tolerates losses.

Benny Landa  credit: Einat Levron Landa Digital Printing granted protection from creditors

The stay of proceedings is until the end of August. The company owes NIS 1.7 billion, mainly arising from investors' loans.

Beyond Towers Givatayim credit: Barely Levitzky Kassif architects Akamai in talks to lease 20,000-sq.m. in Givatayim tower

The US company wants to double the current size of its Tel Aviv office as part of its expansion in Israel.

Begin Highway cover Jerusalem credit: Dagan Visual Solutions Kolker Kolker Epstein Architects Jerusalem District C'ttee approves plan to cover Begin Highway

There will be intensive construction above the highway including some 2,000 housing units, 250 units for assisted living, 300 hotel rooms, 30,000 square meters office and commercial space, and 75,000 square meters for public use.

Shekel strengthening sharply credit: Tali Bogdanovsky with Adobe Firefly Shekel at strongest against dollar since April 2022

The record breaking stock market, falling risk premium, high interest rate, and geopolitical developments all support the continued strengthening of the shekel.

Intel fab construction credit: Intel Intel Kiryat Gat expansion frozen for foreseeable future

Amid Intel's financial woes, part of the $25 billion expansion in Israel has been halted while the other part, although completed, is not operational.

Nvidia Mevo Carmel development center credit: Assaf Gilead Mevo Carmel in pole position to house Nvidia Israel campus

Industry experts believe that the Mevo Carmel Science and Industry Park near Yokne'am is the favorite to persuade Nvidia to build its 180,000 square meter campus there.

Ben Gurion airport credit: Tali Bogdanovsky Foreign airlines returning to Israel faster than expected

United Airlines, Lufthansa Group, Wizz Air and Aegean will add dozens of new flights to Ben Gurion airport's departures and arrivals board over the summer and bring down fares.

New construction in Israel credit: Shutterstock Sharp fall in new home sales after restrictions imposed

The Bank of Israel's efforts to restrict developers financing offers saw housing sales record one of its weakest months in the past 25 years, the Finance Ministry reports.

Apple Vision Pro glasses credit: Apple Apple acquires Israeli 3D avatar co TrueMeeting

Apple will integrate TrueMeeting's technology into its Vision Pro smart glasses, which were launched last year.

Xiaomi SU7 credit: PR Israel to import Xiaomi cars

Xiaomi importer Hemilton has formed a joint partnership with the Hamizrahi vehicle importer to bring the Chinese electric vehicles to Israel.

Hermes 900 UAV credit: Elbit Systems Swiss mull cancelling $380m Elbit drone deal - report

"The technical problems with the surveillance drones are apparently so serious that they must be accompanied by a helicopter or another aircraft to avoid collisions," Swiss newspaper NZZ reports.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky BoI grants Tshuva permit to control Isracard

Yitzhak Tshuva's Delek Group will now buy 37% of the shares in credit card company Isracard, giving it a 40% stake.

Wizz Air  credit: Shutterstock/Peter Leczo Wizz Air to restart Tel Aviv flights in August

Wizz Air will gradually reintroduce Israel services, starting with flights from Tel Aviv to Larnaca and Budapest.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018